Table 2.
Summary of clinical response to ARSI after BAT treatment.
| PSA-PFS m | crPFS m | PSA50 (%) | PSA90 | PFS2 m | OS m | ||
|---|---|---|---|---|---|---|---|
| PILOT—any antiandrogen post-BAT | 10 | NA | NA | 90 | 30% | NA | NA |
| RESTORE | |||||||
| Enzalutamide post-BAT (cohort A) | 22 | 5.5 | 4.7 | 68 | 9% | 12.8 | NA |
| Abiraterone post-BAT (cohort B) | 19 | NA | 4.0 | 16 | 0% | 8.1 | NA |
| Enza/abi post-BAT (cohort C) | 18 | 28.7 | NR | 94 | 83% | NR | NA |
| TRANSFORMER | |||||||
| Enzalutamide post-BAT | 36 | 10.9 | NA | 77.8 | 39 | 28.2 | 37.1 |
| BAT post-enzalutamide | 47 | 1.1 | NA | 21.3 | 2 | 19.6 | 30.2 |
| P= | .0001 | .015 | .225 | ||||
| Enzalutamide post-abiraterone | 35 | NA | 4.9 | 28.6 | Ref.15 | ||
| 39 | NA | 2.8 | 12.8 | Ref.16 | |||
| 102 | 3 | NA | 29 | Ref.17 | |||
| 214 | 5.7 | 8.1 | 27 | Ref.18 | |||